Neuropeptide Y receptors as targets of obesity treatment

Expert Opinion on Therapeutic Patents

Volumn 16, Issue 12, 2006, Pages 1701-1712

  Ishihara, Akane ^a   Moriya, Minoru ^a   MacNeil, Douglas J ^b   Fukami, Takehiro ^a   Kanatani, Aiko ^a  

^a BANYU PHARMACEUTICAL CO LTD   (Japan)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Antiobesity drug; Feeding behaviour; Neuropeptide Y; Receptor antagonist agonist

Indexed keywords

1 NAPHTHALENESULFONIC ACID [4 [(4 AMINO 2 QUINAZOLINYLAMINO)METHYL]CYCLOHEXYLMETHYL]AMIDE; 1,2,3,4 TETRAHYDROCARBAZOLE DERIVATIVE; AMIDE; AMINOPYRIDINE DERIVATIVE; ANTIOBESITY AGENT; BENZAZEPINE DERIVATIVE; BENZIMIDAZOLE DERIVATIVE; BMS 193885; BMS 205749; CG 71683A; CP 671906 01; CP 67190601; FMS 586; GR 231118; GW 438014A; IMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE; LY 357897; N2 DIPHENYLACETYL N (4 UREIDOMETHYLBENZYL)ARGININAMIDE; NALPHA (DIPHENYLACETYL) N (4 HYDROXYBENZYL) DEXTRO ARGININAMIDE; NEUROPEPTIDE Y; NEUROPEPTIDE Y RECEPTOR AGONIST; NEUROPEPTIDE Y RECEPTOR ANTAGONIST; NEUROPEPTIDE Y1 RECEPTOR; NEUROPEPTIDE Y2 RECEPTOR; NEUROPEPTIDE Y3 RECEPTOR; NEUROPEPTIDE Y4 RECEPTOR; NEUROPEPTIDE Y5 RECEPTOR; PHENANTHRIDINE DERIVATIVE; THIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; XANTHENE DERIVATIVE;

ANOREXIA; BEHAVIOR DISORDER; BINDING AFFINITY; COMORBIDITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG PENETRATION; DRUG RESEARCH; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; ENERGY BALANCE; FEEDING BEHAVIOR; FOOD INTAKE; HEALTH CARE DELIVERY; HEALTH CARE NEED; HUMAN; INHIBITION KINETICS; MALAISE; NEUROMUSCULAR DISEASE; NONHUMAN; OBESITY; PATENT; PATIENT CARE; PREVALENCE; RECEPTOR BINDING; REVIEW; WEIGHT REDUCTION;

EID: 33845889758     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.16.12.1701     Document Type: Review

References (89)

1. BRAY GA, BELLANGER T: Epidemiology, trends, and morbidities of obesity and the metabolic syndrome. Endocrine (2006) 29:109-117.
2. Clinical guidelines on the identification, evaluation and treatment of overweight and obesity in adults - the evidence report. National Institutes of Health. Obes. Res. (1998) 6(Suppl. 2):51S-209S.
3. HAMBLY C, SPEAKMAN JR: Contribution of different mechanisms to compensation for energy restriction in the mouse. Obese. Res. (2005) 13:1548-1557.
4. TATEMOTO K, CARLQUIST M, MUTT V: Neuropeptide Y - a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide. Nature (1982) 296:659-660.
5. STANLEY BG: Neuropeptide Y in multiple hypothalamic sites controls eating behavior, endocrine, and autonomic systems for body energy balance. In: The Biology of Neuropeptide Y and Related Peptides. Colmers WF, Wahlestedt C (Ed.). Humana Press/Totowa, NJ (1993):457-509.
6. TURTON MD, O'SHEA D, BLOOM SR: Central effects of neuropeptide Y with emphasis on its role in obesity and diabetes. In: Neuropeptide Y and drug development. Grundemar L, Bloom SR (Ed.). Academic Press, San Diego, (1997):15-39.
7. GUAN XM, YU H, TRUMBAUER M, FRAZIER E, VAN DER PLOEG LH, CHEN H: Induction of neuropeptide Y expression in dorsomedial hypothalamus of diet-induced obese mice. Neuroreport (1998) 9:3415-3419.
8. CSIFFARY A, GORCS TJ, PALKOVITS M: Neuropeptide Y innervation of ACTH-immunoreactive neurons in the arcuate nucleus of rats: a correlated light and electron microscopic double immunolabeling study. Brain Res. (1990) 506:215-222.
9. COWLEY MA, SMART JL, RUBINSTEIN M et al.: Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus. Nature (2001) 411:480-484.
10. EGAWA M, YOSHIMATSU H, BRAY GA: Neuropeptide Y suppresses sympathetic activity to interscapular brown adipose tissue in rats. Am. J. Physiol. (1991) 260:R328-R334.
11. JOLICOEUR FB, BOUALI SM, FOURNIER A et al.: Neurobehavioral profile of neuropeptide Y. Brain Res. Bull. (1991) 26:265-268.
12. STANLEY BG, KYRKOULI SE, LAMPERT S, LEIBOWITZ SF: Neuropeptide Y chronically injected into the hypothalamus: a powerful neurochemical inducer of hyperphagia and obesity. Peptides (1986) 7:1189-1192.
13. ERIKSON JC, HOLLOPETER G, PALMITER RD: Attenuation of the obesity syndrome of oblob mice by the loss of neuropeptide Y. Science (1996) 274:1704-1707.
14. BLOMQVIST AG, HERZOG H: Y-receptor subtypes - how many more? Trends Neurosci. (1997) 20:294-298.
15. BATTERHAM RL, COWLEY MA, SMALL CJ et al.: Gut hormone PYY (3-36) physiologically inhibits food intake. Nature (2002) 418:650-654.
16. KATSUURA G, ASAKAWA A, INUI A: Roles of pancreatic polypeptide in regulation of food intake. Peptides (2002) 23:323-329.
17. WYSS P, STRICKER-KRONGRAD A, BRUNNER L et al.: The pharmacology of neuropeptide Y (NPY) receptor-mediated feeding in rats characterizes better Y5 than Y1, but not Y2 or Y4 subtypes. Regul. Pept. (1998) 75-76:363-371.
18. MULLINS D, KIRBY D, HWA J, GUZZI M, RIVIER J, PARKER E: Identification of potent and selective neuropeptide Y Y1 receptor agonists with orexigenic activity in vivo. Mol. Pharm. (2001) 60:534-540.
19. DANIELS AJ, MATTHEWS JE, SLEPETIS RJ et al.: High-affinity neuropeptide Y receptor antagonists. Proc. Natl. Acad. Sci. USA (1995) 92:9067-9071.
20. KANATANI A, ITO J, ISHIHARA A et al.: NPY-induced feeding involves the action of a Y1-like receptor in rodents. Regul. Pept. (1998) 75-76;409-415.
21. MOLLEREAU C, GOUARDERES C, DUMONT Y et al.: Agonist and antagonist activities on human NPFF(2) receptors of the NPY ligands GR231118 and BIBP3226. Br. J. Pharmacol. (2001) 133:1-4.
22. 2 (BW1911U90). J. Med. Chem. (2001) 44:1479-1482.
23. KASKA, RAGO L, HARRO J: Evidence for involvement of neuropeptide Y receptors in the regulation of food intake: studies with Y1 selective antagonist BIBP3226. Br. J. Pharmacol. (1998) 124:1507-1515.
24. ENGSTROM M, WURSTER S, SAVOLA J-M, PANULA P: Functional properties of Pfr(Tic)amide and BIBP3226 at human neuropeptide FF2 receptors. Peptides (2003) 24:1947-1954.
25. WIELAND HA, ENGEL W. EBERLEIN W, RUDOLF K, DOODS HN: Subtype selectivity of the novel nonpeptide neuropeptide Y Y1 receptor antagonist BIB03304 and its effect on feeding in rodents. Br. J. Pharmacol. (1998) 125:549-555.
26. POINDEXTER GS, BRUCE MA, BREITENBUCHER JG et al.: Dihydropyridine neuropeptide Y Y1 receptor antagonists 2. Bioisosteric urea replacements. Bioorg. Med. Chem. (2004) 12:507-521.
27. POINDEXTER GS, BRUCE MA, LEBOULLUEC KL et al.: Dihydropyridine neuropeptide Y Y(1) receptor antagonists. Bioorg. Med. Chem. Lett. (2002) 12:379-382.
28. HIPSKIND PA, LOBB KL, NIXON JA et al.: Potent and selective 1,2,3-trisubstituted indole NPY Y-1 antagonists. J. Med. Chem. (1997) 40:3712-3714.
29. CARPINO A, CASSELLA J, DARROW JW et al.: Structure-activity relationships within a series of pyrazolopyrimidine NPY-Y1 receptor antagonists. The 222nd ACS National Meeting. Chicago, IL, USA (2001) 283.
30. KANATANI A, KANNO T, ISHIHARA A et al.: The novel neuropeptide Y Y1 receptor antagonist J-104870: a potent feeding suppressant with oral bioavailability. Biochem. Biophys. Res. Commun. (1999) 266:88-91.
31. KANATANI A, HATA M, MASHIKO S et al.: A typical Y1 receptor regulates feeding behaviors: effects of a potent and selective Y1 antagonist, J-115814. Mol. Pharmacol. (2001) 59:501-505.
32. ISHIHARA A, KANATANI A, OKADA M et al.: Blockade of body weight gain and plasma corticosterone levels in Zucker fatty rats using an orally active neuropeptide Y Y1 antagonist. Br. J. Pharmacol. (2002) 136:341-346.
33. MURAKAMI Y, HARA H, OKADA TJ et al.: 1,3-Disubstituted benzazepines as novel, potent, selective neuropeptide YY1 receptor antagonists. J. Med Chem. (1999) 42:2621-2632.
34. DI FABIO R, GIOVANNINI R, BERTANI B et al.: Synthesis and SAR of substituted tetrahydrocarbazole derivatives as new NPY-1 antagonists. Bioorg. Med. Chem. (2006) 16:1749-1752
35. PONS J, LEE EW, Li L, KITLINSKA J: Neuropeptide Y: multiple receptors and multiple roles in cardiovascular diseases. Curr. Opin. Investig. Drugs (2004) 5:957-962.
36. WETTSTEIN JG, FARLEY B, JUNIEN JL: Central nervous system pharmacology of neuropeptide Y. Pharmacol. Ther. (1995) 65:397-414.
37. MARKIEWICZ W, JAROSZEWSKI JJ, BOSSOWSKA A, MAJEWSKI M: NPY: its occurrence and relevance in the female reproductive system. Folia. Histochem. Cytobiol. (2003) 41:183-192.
38. GERALD C, WALKER MW, CRISCIONE L et al.: A receptor subtype involved in neuropeptide-Y-induced food intake. Nature (1996) 382:168-171.
39. HWA JJ, WITTEN MB, WILLIAMS P et al.: Activation of the NPY Y5 receptor regulates both feeding and energy expenditure. Am. J. Physiol. (1999) 277:R1428-R1434.
40. PARKER EM, BALASUBRAMANIAMB A, GUZZIA M et al.: [D-Trp34] neuropeptide Y is a potent and selective neuropeptide Y Y5 receptor agonist with dramatic effects on food intake. Peptides (2000) 21:393-399.
41. MASHIKO S, ISHIHARA A, IWAASA H et al.: Characterization of neuropeptide Y (NPY) Y5 receptor-mediated obesity in mice: chronic intracerebroventricular infusion of D-Trp(34)NPY. Endocrinology (2003) 144:1793-1801.
42. CRISCIONE L, RIGOLLIER P, BATZL-HARTMANN C et al.: Food intake in free-feeding and energy-deprived lean rats is mediated by the neuropeptide Y5 receptor. J. Clin. Invest. (1998) 102:2136-2145.
43. DELLA ZUANA O, SADLO M, GERMAIN M et al: Reduced food intake in response to CGP 71683A may be due to mechanisms other than NPY Y5 receptor blockade. Int. J. Obes. Relat. Metab. Disord. (2001) 25:84-94.
44. TURNBULL AV, ELLERSHAW L, MASTERS DJ et al.: Selective antagonism of the NPY Y5 receptor does not have a major effect on feeding in rats. Diabetes (2002) 51:2441-2449.
45. ELLIOTT RL, OLIVER RM, HAMMOND M et al.: In vitro and in vivo characterization of 3-[2-[6-(2-tert-butoxy-ethoxy)pyridin-3-yl]-1H- imidazol-4-yl]-benzonitrile hydrochloride salt, a potent and selective NPY5 receptor antagonist. J. Med. Chem. (2003) 46:670-673.
46. DANIELS AJ, GRIZZLE MK, WIARD RP, MATTHEWS JE, HEYER D: Food intake inhibition and reduction in body weight gain in lean and obese rodents treated with GW438014A, a potent and selective NPY-Y5 receptor antagonist. Regl. Pep. (2002) 106:47-54.
47. ISHIHARA A, KANATANI A, MASHIKO S et al.: A neuropeptide Y Y5 antagonist selectively ameliorates body weight gain and associated parameters in diet-induced obese mice. Proc. Natl. Acad. Sci. USA (2006) 103:7154-7158.
48. KANATANI A, ISHIHARA A, IWAASA H et al.: L-152,804: orally active and selective neuropeptide Y Y5 receptor antagonist. Biochem. Biophys. Res. Commun. (2000) 272:169-173.
49. KAKUI N, TANAKA J, TABATA Y et al.: Pharmacological characterization and feeding-suppressive property of FMS586 [3-(5,6,7,8-tetrahydro-9-isopropyl-carbazol-3-yl)- 1-methyl-1-(2-pyridin-4-yl-ethyl)-urea hydrochloride], a novel, selective and orally active antagonist for neuropeptide Y Y5 receptor. J. Pharmacol. Exp. Ther. (2006) 317:562-570.
50. ERONDU NE, GANTZ I, MUSSER BJ et al.: Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults. Cell Metabolism (2006) 4:275-282.
51. PADWAL R, LI SK, LAU DC: Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. Int. J. Obes. Relat. Metab. Disord. (2003) 27:1437-1446.
52. VAN GAAL LF, RISSANEN AM, SCHEEN AJ, ZIEGLER O, ROSSNER S; RIO-EUROPE STUDY GROUP: Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet (2005) 365:1389-1397.
53. WOLDBYE DP, KOKAIA M: Neuropeptide Y and seizures: effects of exogenously applied ligands. Neuropeptides (2004) 38:253-260.
54. SCHROEDER JP, OVERSTREET DH, HODGE CW: The neuropeptide-Y Y5 receptor antagonist L-152,804 decreases alcohol self-administration in inbred alcohol-preferring (iP) rats. Alcohol (2005) 36:179-186.
55. GAMBLE KL, EHLEN JC, ALBERS HE: Circadian control during the day and night: role of neuropeptide Y Y5 receptors in the suprachiasmatic nucleus. Brain Res. Bull. (2005) 65:513-519.
56. CHEN X, DIMAGGIO DA, HAN SP, WESTFALL TC: Autoreceptor-induced inhibition of neuropeptide Y release from PC-12 cells is mediated by Y2 receptors. Am. J. Physiol. (1997) 273:H1737-H1744.
57. TSCHOP M, CASTANEDA TR, JOOST HG et al.: Does gut hormone PYY3-36 decrease food intake in rodents? Nature (2004) 430:165-167.
58. BATTERHAM RL, COHEN MA, ELLIS SM et al.: Inhibition of food intake in obese subjects by peptide YY3-36. N. Engl. J. Med. (2003) 349:941-948.
59. SMALL CJ, BLOOM SR: The therapeutic potential of gut hormone peptide YY3-36 in the treatment of obesity. Expert Opin. Investig. Drugs (2005) 14:647-653.
60. HUNG CC, PIRIE F, LUAN J et al.: Studies of the peptide YY and neuropeptide Y2 receptor genes in relation to human obesity and obesity-related traits. Diabetes (2004) 53:2461-2666.
61. MA L, TATARANNI PA, HANSON RL et al.: Variations in peptide YY and Y2 receptor genes are associated with severe obesity in Pima Indian men. Diabetes (2005) 54:1598-1602.
62. SAINSBURY A, SCHWARZER C, COUZENS M et al.: Important role of hypothalamic Y2 receptors in body weight regulation revealed in conditional knockout mice. Proc. Natl. Acad. Sci. USA (2002) 99:8938-8943.
63. NAVEILHAN P, HASSANI H, CANALS JM et al.: Normal feeding behavior, body weight and leptin response require the neuropeptide Y Y2 receptor. Nature Med. (1999) 5:1188-1193.
64. SAINSBURY A, SCHWARZER C, COUZENS M, HERZOG H: Y2 receptor deletion attenuates the Type 2 diabetic syndrome of oblob mice. Diabetes (2002) 51:3420-3427.
65. ZUKOWSKA Z: NPY in stress and vascular remodeling: what can we treat with NPY receptor antagonists? The 8th International NPY Conference. St. Petersburg, FL, USA (2006) V:02.
66. ALLISON SJ, BALDOCK PA, SAINSBURY A et al.: Conditional deletion of hypothalamic Y2 receptors reverts gonadectomy-induced bone loss in adult mice. J. Biol. Chem. (2006) 281:23436-23444.
67. BALDOCK PA, SAINSBURY A, COUZENS M et al.: Hypothalamic Y2 receptors regulate bone formation. J. Clin. Invest. (2002) 109:915-921.
68. BARD JA, WALKER MW, BRANCHEK TA, WEINSHANK RL: Cloning and functional expression of a human Y4 subtype receptor for pancreatic polypeptide, neuropeptide Y and peptide YY. J. Biol. Chem. (1995) 270:26762-26765.
69. LARSEN PJ, KRISTENSEN P: The neuropeptide Y (Y4) receptor is highly expressed in neurones of the rat dorsal vagal complex. Mol. Brain Res. (1997) 48:1-6.
70. PARKER RM, HERZOG H: Regional distribution of Y-receptor subtype mRNAs in rat brain. Eur. J. Neurosci. (1999) 11:1431-1448.
71. CAMPBELL RE, SMITH MS, SUMMER EA et al.: Orexin neurons express a functional pancreatic polypeptide Y4 receptor. J. Neuroscience (2003) 23:1487-1497.
72. ASAKAWA A, INUI A, YUZURIHA H et al.: Characterization of the effects of pancreatic polypeptide in the regulation of energy balance. Gastroenterology (2003) 124:1325-1336.
73. GETTYS TW, GARCIA R, SAVAGE K, WHITCOMB DC, KANAYAMA S, TAYLOR IL: Insulin-sparing effects of pancreatic polypeptide in congenitally obese rodents. Pancreas (1991) 6:46-53.
74. MCTIGUE DM, HERMANN GE, ROGERS RC: Effect of pancreatic polypeptide on rat dorsal vagal complex neurons. J. Physiol. (1997) 499:475-483.
75. OKUMURA T, PAPPAS TN, TAYLOR IL: Intracisternal injection of pancreatic polypeptide stimulates gastric emptying in rats. Neurosci. Lett. (1994) 178:167-170.
76. UENO N, INUI A, IWAMOTO M et al.: Decreased food intake and body weight in pancreatic polypeptide-overexpressing mice, Gastroenterology (1999) 117:1427-1432.
77. BATTERHAM RL, LE ROUX CW, COHEN MA et al.: Pancreatic polypeptide reduces appetite and food intake in humans. J. Clin. Endocrinol. Metab. (2003) 88:3989-3992.
78. BERNTSON GG, ZIPF WB, O'DORISIO TM, HOFFMAN JA, CHANCE RE: Pancreatic polypeptide infusions reduce food intake in Prader-Willi syndrome. Peptides (1993) 14:497-503.
79. PHENG L-H, PERRON A, QUIRION R et al.: Neuropeptide Y-induced contraction is mediated by neuropeptide Y Y2 and Y4 receptors in the rat colon. Eur. J. Pharmacol. (1999) 374:85-91.
80. FUJIKAWA T, MORIYA R, ITO J et al: Pancreatic polypeptide accelerates lower intestinal motility via Y4 receptor in mice. Japan Society of Smooth Muscle the 48th Annual Meeting. Okayama, Japan (2006) 16.
81. PASIEKA JL, HERSHFIELD N: Pancreatic polypeptide hyperplasia causing watery diarrhea syndrome: a case report. Can. J. Surg. (1999) 42:55-58.
82. PASIEKA JL, HERSHFIELD N, MORTENSON M: Symptomatic pancreatic polypeptide-secreting tumor of the distal pancreas (PPoma). Int. J. Gastrointest. Cancer (2002) 32:153-156,
83. COX HM: A neuroendocrine neighbour of note. The 8th International NPY Conference. St. Petersburg, FL, USA (2006) II:01.
84. POTTER EK, BARDEN JA, MCCLOSKEY MJ et al.: A novel neuropeptide Y analog, N-acetyl [Leu28, Leu31]neuropeptide Y-(24-36), with functional specificity for the presynaptic (Y2) receptor. Eur. J. Pharmacol. (1994) 267:253-262.
85. RIST B, ZERBE O, INGENHOVEN N et al.: Modified, cyclic dodecapeptide analog of neuropeptide Y is the smallest full agonist at the human Y2 receptor. FEBS Lett. (1996) 394:169-173.
86. 2-NH) scan of peptide YY (PYY) active site, PYY(22-36), for interaction with rat intestinal PYY receptors: development of analogues with potent in vivo activity in the intestine. J. Med. Chem. (2000) 43:3420-3427.
87. BALASUBRAMANIAM A, MULLINS DE, LIN S et al.: Neuropeptide Y (NPY) Y4 receptor selective agonists based on NPY (32-36): development of an anorectic Y4 receptor selective agonist with picomolar affinity. J. Med. Chem. (2006) 49:2661-2665.
88. ELLING CE: Selective Y2 versus selective Y4 and combined Y2-Y4 receptor agonists for therapeutic interventions. The 8th International NPY Conference. St. Petersburg, FL, USA (2006) II:02.
89. WITTMANN W, LOACKER S, KAPELLER I, HERZOG H, SCHWARZER C: Y1-receptors regulate the expression of Y2-recepcors in distinct mouse forebrain areas. Neuroscience (2005) 136:241-250.